AUTOMATIC SUBDERMAL INJECTOR SYSTEM (ASIS) Corporation has developed and patented the only
automatic injection system for delivery of injectable products to the optimum spot, just
outside of the fascia, which exists subdermally (between the skin and muscle) or interfascial
(between the deeper muscles). ASIS device creates that bloodless space, enhancing Enbrel's
efficacy and preventing unnecessary distant spread and adverse reactions. This space remains
bloodless as long as the skin is lifted up or filled with an injectable product. Although
ASIS device was initially designed to best administer BOTOX for such muscular conditions as
Upper limb Spasticity, Cervical Dystonia, Chronic Migraine, Strabismus, Blepharospasm, and
Primary Axillary Hyperhidrosis, the technology will also benefit other injectable products,
including: GAMMAGARD for Primary Immunodeficiency (PI) and Insulin for Diabetics, etc.